OncoMatch/Clinical Trials/NCT07172386
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Is NCT07172386 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Toripalimab and axitinib for renal cell carcinoma (rcc).
Treatment: Toripalimab and axitinib — This is a phase II study to determine the efficacy and safety of Super-selective tumor artery embolization combined with toripalimab and axitinib as treatment for patients with the advanced kidney cancer . Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for three to four consecutive cycles combined with axitinib administered for four consecutive cycles in the preoperative and patients need to continue taking the drug for a year after surgery
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage CT2N0M0 WITH GRADE 4 OR SARCOMATOID FEATURE, CT3-4N0M0, CTANYN1M0, M1 THAT CAN BE RETURNED TO M0 THROUGH LOCAL THERAPY (clinical TNM)
Grade: Grade 4 or sarcomatoid feature (for cT2N0M0)
cT2N0M0 with Grade 4 or sarcomatoid feature; cT3-4N0M0; cTanyN1M0; M1 that can be returned to M0 through local therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Prior receipt of radiotherapy
Cannot have received: chemotherapy
Prior receipt of chemotherapy
Cannot have received: long-term or high-dose corticosteroid therapy
Prior receipt of long-term or high-dose corticosteroid therapy
Cannot have received: surgery
Prior receipt of surgery
Cannot have received: molecular targeted therapy
Prior receipt of molecular targeted therapy
Cannot have received: PD-1/PD-L1 therapy
Prior treatment with other PD-1/PD-L1 therapies
Lab requirements
Blood counts
neutrophil count ≥ 1.5x10^9/L, platelet count ≥ 100x10^9/L, hemoglobin ≥ 9.0 g/dl (can be maintained by blood transfusion)
Liver function
total bilirubin ≤1.5 ULN, alanine aminotransferase and aspartate aminotransferase ≤1.5 ULN
Organ function level must meet the following requirements: Hematological indexes: neutrophil count ≥ 1.5x10^9/L, platelet count ≥ 100x10^9/L, hemoglobin ≥ 9.0 g/dl (can be maintained by blood transfusion); Liver function: total bilirubin ≤1.5 ULN, alanine aminotransferase and aspartate aminotransferase ≤1.5 ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify